From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

On the same day North Carolina hospitals reported a record number of COVID-19 patients in intensive care units across the state, Gov. Roy Cooper signaled he will take action expanding access to a ...

Important adverse events included infusion-related and hypersensitivity reactions in 25 of 306 immunocompromised participants (8.2%) who received pemivibart and anaphylaxis in 4 of 623 participants (0 ...

PHILADELPHIA (WPVI) -- It's the only authorized treatment that can help keep people with COVID-19 out of the hospital, but hundreds-of-thousands of doses aren't being used. The effectiveness of ...

Invivyd, Inc. has launched a discovery program for a monoclonal antibody (mAb) targeting measles, following requests from healthcare providers for a treatment option for active infections and ...

The dominance of the Delta strain of COVID-19 combined with Alabama’s low vaccination rate has led experts to turn to monoclonal antibody infusion, a treatment in which infected individuals are ...

The FDA has authorized a new treatment that may help immunocompromised people be protected from COVID-19. The treatment is a monoclonal antibody infusion that is expected to be available this April.

And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...

For patients who rely on monoclonal antibodies and other biologic drugs, treatment often means hours tethered to an IV pole while a clear bag slowly empties into a vein. A new generation of ...